Zynerba Pharma Inc. (NASDAQ: ZYNE) stock gained by 4.68% at the last close while the ZYNE stock price falls by 1.06% during the pre-market session. Zynerba Pharmaceuticals is a pioneer of pharmaceutically developed transdermal cannabinoid treatments for neuropsychiatric conditions that are rare or near-rare.
What is happening?
ZYNE announced on May 17, 2021, that it would give an oral podium presentation and a poster presentation at the Virtual ISPOR 2021 meeting, which will be held May 17-20, 2021. On the Virtual ISPOR 2021 program gallery and the Zynerba corporate website, both the podium and poster presentations are visible. The International Society for Health Economics and Outcomes Analysis (ISPOR) is the world’s leading specialist society for health economics and outcomes research (HEOR).
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
The oral podium presentation, named as “Caregiver-Perceived Behavioral Challenges in Fragile X Syndrome (FXS) and Their Measurement Using the Aberrant Behavior Checklist-Community FXS Specific Scoring,” shows that the ABC-CFXS subscales used to assess the primary and main secondary endpoints in Zynerba’s CONNECT-FX trial identify behavior problems relevant to patients with FXS and their measurement through using Aberrant Behavior Checklist.
The poster, named as “Meaningful Improvement Thresholds for the Aberrant Behavior Checklist-Community Fragile X Syndrome (ABC-CFXS) in Children and Adolescents with FXS,” defines responder thresholds for the ABC-CFXS social avoidance, irritability, and socially unresponsive/lethargic subscales that may be predictive of meaningful treatment gain. As a result, as illustrated in CONNECTFX, these thresholds will be used to evaluate clinically relevant therapeutic outcomes at the actual patient level in clinical studies with children and adolescents with FXS.
Joseph M. Palumbo Chief Medical Officer commented:
These findings suggest that the ABC-CFXS subscales capture traits that are essential and understandable to parents of children with FXS. As a result, they continue to believe that these subscales are suitable for calculating clinical trial endpoints in FXS.